Zoetis Stock Forecast for 2023 - 2025 - 2030
Updated on 06/04/2023
Zoetis Stock Forecast and Price Target
The average target price set lately by nine experts for Zoetis to reach by the end of the year is $205.00, which would imply a potential upside of approximately 19.27 percent from the previous closing price if it were to be achieved. This prediction is based on a high estimate of $250.00 and a low estimate of $170.00. Even if you are not interested in ZTS stock, you should still be aware of its competitors.
19.27% Upside
Zoetis Fair Value Forecast for 2023 - 2025 - 2030
Zoetis's Price has seen growth In the last two years, going from $129.44 to $167.13 – a gain of 29.12% In the next year, analysts believe that Fair Value will reach $204.83 – an increase of 22.55%. For the next eight years, the forecast is forFair Value to grow by 124.68%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly & Co | Outperform |
14
|
$442.33 | Buy/Sell | $333.19 | -9.57% |
| A005930 Stock Forecast | Samsung Electronics | Buy |
10
|
₩59.00k | Buy/Sell | ₩75.05k | 27.12% |
| MRK Stock Forecast | Merck | Outperform |
5
|
$112.52 | Buy/Sell | $99.57 | 4.87% |
| NOVN Stock Forecast | Novartis | Hold |
10
|
CHF85.77 | Buy/Sell | CHF103.75 | 9.89% |
| ABT Stock Forecast | Abbott Laboratories | Outperform |
10
|
$104.20 | Buy/Sell | $121.64 | 19.96% |
Zoetis Revenue Forecast for 2023 - 2025 - 2030
Zoetis's Revenue has seen growth In the last two years, going from $6.26B to $7.78B – a gain of 24.22% In the next year, analysts believe that Revenue will reach $9.04B – an increase of 16.26%. For the next eight years, the forecast is forRevenue to grow by 89.37%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BMY Stock Forecast | Bristol-Myers Squibb Co | Outperform |
2
|
$65.66 | Buy/Sell | $80.99 | 26.41% |
| AMGN Stock Forecast | Amgen Inc | Hold |
7
|
$218.07 | Buy/Sell | $268.00 | 27.48% |
| SAN Stock Forecast | Sanofi | Outperform |
10
|
91.12€ | Buy/Sell | 108.44€ | 20.72% |
.jpg)
Zoetis Dividend per Share Forecast for 2023 - 2025 - 2030
In the last two years, Dividend per Share for Zoetis has grown by 51.52%, going from $0.66 to $1.00. In the coming year, analysts are expecting an increase in Dividend per Share, predicting it will reach $1.42 – an increase of 42.00%. Over the next eight years, experts anticipate that Dividend per Share growth for Zoetis will be 221.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| GSK Stock Forecast | GSK | Outperform |
16
|
£1.37k | Buy/Sell | £16.95 | -98.82% |
| BAYN Stock Forecast | Bayer | Outperform |
7
|
52.61€ | Buy/Sell | 74.54€ | 43.51% |
| BIIB Stock Forecast | Biogen Inc | Outperform |
11
|
$300.20 | Buy/Sell | $322.44 | 8.26% |
Zoetis Free Cash Flow Forecast for 2023 - 2025 - 2030
In the last two years, Zoetis's Free Cash Flow has increased by 30.04%, going from $1.34B to $1.74B. In the next year, analysts are expecting an increase in Free Cash Flow, predicting it will reach $2.63B – an increase of 51.35%. The Zoetis forecast is for Free Cash Flow to reach $4.49B or grow by 158.47%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ADM Stock Forecast | Archer-Daniels-Midland Co | Outperform |
4
|
$71.97 | Buy/Sell | $94.21 | 37.56% |
| IDXX Stock Forecast | IDEXX Laboratories Inc | Outperform |
16
|
$470.83 | Buy/Sell | $539.90 | 6.20% |
| 4901 Stock Forecast | FUJIFILM Holdings | Outperform |
18
|
¥6.63k | Buy/Sell | ¥0.00 | 58.42% |
Zoetis Net Income Forecast for 2023 - 2025 - 2030
Zoetis's Net Income has grown in the last two years, jumping from $1.50B to $2.04B – an increase of 35.80%. In the next year, analysts predict that Net Income will reach $2.72B – an increase of 33.29%. For the next eight years, the forecast is for Net Income to grow by 132.32%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| VTRS Stock Forecast | Viatris | Outperform |
8
|
$9.33 | Buy/Sell | $13.70 | 44.69% |
| ELAN Stock Forecast | Elanco Animal Health | Outperform |
13
|
$9.22 | Buy/Sell | $0.00 | 247.07% |
| PRGO Stock Forecast | Perrigo | Buy |
16
|
$32.99 | Buy/Sell | $47.75 | 43.98% |
Zoetis EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Zoetis's EBITDA has grown, increasing from $2.48B to $3.21B – an increase of 29.21%. For next year, the 7 analysts predict EBITDA of $3.98B, which would mean an increase of 24.01%. Over the next eight years, the pros' prediction is EBITDAof $6.66B, which would mean a eight-year growth forecast of 107.80%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| DPH Stock Forecast | Dechra Pharmaceuticals PLC | Buy |
18
|
£3.63k | Buy/Sell | £39.93 | -98.90% |
| BHC Stock Forecast | Bausch Health Companies | Hold |
15
|
$8.23 | Buy/Sell | $34.09 | -8.87% |
| VETO Stock Forecast | Vetoquinol | Outperform |
18
|
122.80€ | Buy/Sell | 151.98€ | 23.37% |
Zoetis EBIT Forecast for 2023 - 2025 - 2030
Zoetis's EBIT has increased by 34.05% In the last two years, going from $2.10B to $2.81B. In the next year, analysts expect EBIT to reach $3.63B – an increase of 28.99%. For the next eight years, the forecast is for EBIT to grow by 116.99%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| MNKP.F Stock Forecast | Mallinckrodt | - |
12
|
$19.00 | Buy/Sell | $1.50 | 9.11% |
| HSKA Stock Forecast | Heska | Outperform |
12
|
$119.84 | Buy/Sell | $154.20 | 29.34% |
| PAHC Stock Forecast | Phibro Animal Health | Hold |
18
|
$13.75 | Buy/Sell | $20.00 | 60.00% |
Zoetis EPS Price Prediction Forecast for 2023 - 2025 - 2030
Zoetis's EPS has seen growth In the last two years, going from $3.64 to $4.70 – a gain of 29.12% In the next year, analysts believe that EPS will reach $5.76 – an increase of 22.55%. For the next eight years, the forecast is forEPS to grow by 124.68%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 523261 Stock Forecast | Venky's (India) | - |
14
|
Rp2.10k | Buy/Sell | Rp561.00 | 11.56% |
| ENDP Stock Forecast | Endo International | Underperform |
14
|
$0.41 | Buy/Sell | $0.00 | 143.90% |
| ICCC Stock Forecast | ImmuCell | - |
0
|
$4.92 | Buy/Sell | $0.00 | 96.14% |
.jpg)